MedTrace Logo

Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction

NCT01160627 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 720

Last updated 2013-03-22

No results posted yet for this study

Summary

OBJECTIVE: To evaluate the efficacy of prevention of contrast induced nephropathy in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

DESIGN: Prospective study. SETTING: Three-center study Acute kidney injury was defined as a rise in creatinine \>25% from baseline Serum creatinine will be measured at baseline and each day for the following 3 days and at 30 days.

Patients will be randomised to:

1. Standard treatment
2. Standard treatment + acetylcystein for 2 days
3. Standard treatment + Sodium bicarbonate 500 ml / followed by 100 ml/h for 5 hours
4. Standard treatment + acetylcystein for 2 days + Sodium bicarbonate 500 ml / followed by 100 ml/h for 5 hours

Conditions

  • Contrast Induced Nephropathy

Interventions

OTHER

Hydration

Saline hydration

DRUG

Acetylcysteine

Acetylcystein tablets for 2 days

DRUG

Sodium bicarbonate

Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours

DRUG

Combined Acetylcystein and Sodium Bicarbonate

Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours combined with acetylcystein tablets for 2 days

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Per Thayssen, MD DMSci · Odense University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01160627 on ClinicalTrials.gov